Valutazione economica e analisi di budget impact di S-1 (tegafur/gimeracil/oteracil) in pazienti con carcinoma gastrico avanzato

Objective The aim of this study was to assess whether S-1 might represent a valuable therapeutic option for patients with advanced gastric cancer in comparison to other available therapies (5-FU, capecitabine), considering both costs and outcomes associated with the different therapeutic strategies. The perspective of the analysis was that of the Italian National Health Service (NHS).